Roger Barker: Beyond the “Breakthrough”

“I Don’t Think We Need a Cure”

Asked directly when Parkinson’s disease might finally be cured, Barker gave an answer that initially sounded almost counterintuitive.

“I don’t think we need a cure,” he said.

The statement was not pessimistic. Nor was it a retreat from treatment. Instead, it reflected a different way of thinking about neurodegenerative disease itself.

The average age of Parkinson’s diagnosis is around 70. For many patients, life expectancy differs relatively little from the broader population. The central challenge is often not lifespan itself, but the gradual accumulation of disability over time.

“If you can slow it down by 50 percent,” Barker said, “and pick people up early on, you’ve probably done it.”

In that framework, the goal shifts from eliminating Parkinson’s entirely to delaying its most debilitating phases for as long as possible.

Barker described a future in which researchers identify high-risk patients years before classical symptoms emerge - perhaps through REM sleep behavior disorder or other early biological markers - and begin treatment while degeneration is still limited.

“So instead of getting it 10 or 15 years later,” he said, “you get it 20 or 30 years later.”

The arithmetic, he argued, changes everything.

“You’ll be over 120 before you’re running into problems.”

The idea reflects a broader transition underway across neurodegeneration research. Increasingly, scientists are beginning to think less in terms of absolute cures and more in terms of slowing biological aging, delaying pathology and extending healthy neurological function.

The distinction may sound semantic. Barker believes it is fundamental.

Stem Cells and the Limits of Repair

That same realism shapes Barker’s views on stem-cell therapies, one of the most closely watched areas in Parkinson’s research.

Barker has spent years working on cell replacement strategies designed to restore dopamine-producing neurons lost during disease progression. Multiple companies and academic groups are now conducting clinical trials using stem-cell-derived dopamine neurons implanted into patients’ brains.

“There are probably 15 or 20 companies running trials,” Barker said.

Early results have been encouraging in at least one respect.

“They’ve shown they’re feasible,” he said. “The product itself is safe.”

But efficacy remains less certain. Researchers still do not fully understand the optimal dose, delivery methods, patient selection criteria or immune therapies needed to keep transplanted cells alive long term.

“I think there’s enough there to give us optimism,” Barker said. “But I think the field mustn’t run ahead of its data.”

His caution becomes especially sharp when discussing public misconceptions around stem-cell therapies.

“The biggest misconception,” he said, “is that dopamine stem-cell therapies are a cure.”

“They’re just replacing dopamine,” Barker said. “The disease process itself carries on.”

The distinction matters enormously. Cell replacement may repair one damaged circuit while leaving the broader disease biology untouched.

For Barker, that distinction reflects a larger misunderstanding that has long shaped Parkinson’s research itself: the assumption that replacing what is lost necessarily stops the underlying disease process.

Increasingly, researchers suspect the biology is far more complicated than that.

Pollution and Inflammation

Like many researchers at the World Parkinson Congress, Barker increasingly believes environmental exposures may play an important role in neurodegeneration.

“I think the role of pollutants and intoxicants is going to be quite important,” he said.

But his interest extends beyond pesticides or industrial toxins alone.

Barker’s laboratory has been studying transposable elements - ancient viral sequences embedded inside human DNA. Much of the genome consists of these dormant viral remnants, normally held inactive by cellular regulatory systems. As the brain ages, however, those control systems may weaken.

“We found in the Parkinson’s brain they start getting re-expressed,” Barker said.

To the immune system, such reactivated viral fragments may resemble genuine infections.

“As far as your brain’s concerned,” Barker said, “that’s a virus. I better attack it.”

The result may be chronic inflammatory activation gradually contributing to neurodegeneration. Pollution, infections and aging-related genomic instability may therefore converge through common inflammatory pathways.

“I think there may be some commonality,” Barker said.

The same broader systems thinking increasingly extends beyond molecular biology alone. Researchers have also become far more interested in exercise, metabolism, sleep and environmental health than they were even fifteen years ago.

Exercise, Diet and Agency

Despite his emphasis on complex biology, Barker repeatedly returned to something far simpler: exercise.

“I think we’ve underestimated the impact of exercise and diet,” he said.

For years, such interventions were often treated as secondary or “fluffy” science compared with molecular therapeutics. Increasingly, however, researchers view them as biologically meaningful.

Exercise affects inflammation, metabolism, cardiovascular health, stress resilience and social interaction simultaneously.

“You don’t need a doctor to tell you to do it,” Barker said.

That autonomy matters.

“It’s very empowering,” he said.

The same perspective also shapes his advice to newly diagnosed patients. If diagnosed himself, Barker said he would focus heavily on exercise, diet, research participation and maintaining realistic expectations.

He would also avoid becoming consumed by online forums and exaggerated medical claims.

“I would keep off the internet with all of the different forums,” he said.

Instead, he said he would search carefully for clinical trials worth joining and focus on maintaining long-term health as effectively as possible.

The Moonshot Problem

At one point in the interview, Barker unexpectedly launched into a detailed discussion of the Apollo program. He has become slightly obsessed with it, he admitted.

“The average age of the people in mission control when they landed on the moon was 28,” he said.

What fascinates him is not simply the technological achievement itself, but the coordination. Thousands of people worked toward a single clearly defined objective backed by enormous resources and urgency.

“You could move mountains,” Barker said.

Parkinson’s research, however, lacks that kind of clarity.

“We know what landing the man on the moon is,” he said.

But unlike the Apollo program, the individual scientific roles are far less obvious.

“Am I making the lunar module?” Barker asked. “Or am I in charge of the engines?”

The biological complexity of Parkinson’s makes coordination far more difficult than engineering. Still, Barker believes the field is becoming more collaborative. Open-access datasets, international consortia and philanthropic initiatives such as ASAP - Aligning Science Across Parkinson’s - are accelerating cooperation across institutions and disciplines.

Yet modern science still contains tensions between openness, competition, career incentives and intellectual ownership.

Young researchers, Barker noted, still depend heavily on authorship prestige and grant success. Those structures can discourage full collaboration even when researchers support it philosophically.

“How we recognize people’s contributions,” Barker said, “has to change.”

The culture of science itself, he argues, may ultimately matter almost as much as the science.

Beyond the Beginning

Asked where neuroscience currently stands in its understanding of Parkinson’s disease - at the beginning, middle or approaching a breakthrough - Barker paused.

“I think we’re beyond the beginning,” he said.

Compared with the first World Parkinson Congress, the field now possesses vastly more sophisticated genetic tools, imaging technologies and pathological data. Researchers can analyze individual cells, map spatial transcriptomics and study molecular changes across tissue with extraordinary precision.

The challenge is no longer merely generating data. The challenge is integrating it.

“I think we have a lot of the parts that are there,” Barker said.

But he warned again against reducing Parkinson’s to any single pathway or explanation.

“You don’t want to be too reductionist,” he said.

Because Parkinson’s, ultimately, may resist simplicity itself.